{"id":954,"date":"2018-02-06T15:31:54","date_gmt":"2018-02-06T15:31:54","guid":{"rendered":"https:\/\/www.ggkmedia.com\/?p=954"},"modified":"2020-03-30T21:05:06","modified_gmt":"2020-03-30T19:05:06","slug":"double-bond-pharmaceutical-blir-distributor-av-inofer","status":"publish","type":"post","link":"https:\/\/www.drugsson.com\/sv\/double-bond-pharmaceutical-blir-distributor-av-inofer\/","title":{"rendered":"Double Bond Pharmaceutical blir distribut\u00f6r av Inofer"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-background-repeat:repeat;--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:90px;--awb-padding-bottom:90px;--awb-background-color:#eaf7ff;--awb-border-sizes-top:0px;--awb-border-sizes-bottom:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-padding-top:50px;--awb-padding-right:50px;--awb-padding-bottom:30px;--awb-padding-left:50px;--awb-bg-color:#ffffff;--awb-bg-color-hover:#ffffff;--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-1\"><h3>Double Bond Pharmaceutical blir distribut\u00f6r av Inofer<\/h3>\n<\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-padding-top:50px;--awb-padding-right:50px;--awb-padding-bottom:50px;--awb-padding-left:50px;--awb-bg-color:#ffffff;--awb-bg-color-hover:#ffffff;--awb-bg-size:cover;--awb-border-color:#25afb4;--awb-border-bottom:8px;--awb-border-style:solid;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-2\"><p>Double Bond Pharmaceutical och Laboratoire XO har idag, den 2018-02-06, signerat ett distributionsavtal f\u00f6r Inofer i Sverige, Norge, Danmark och Finland. Inofer \u00e4r ett j\u00e4rntillskott som best\u00e5r av ferrous succinat som \u00e4r en kemisk j\u00e4rnform k\u00e4nd f\u00f6r att l\u00e4ttare upptas i kroppen hos m\u00e4nniskor med f\u00f6rs\u00e4mrat upptag av j\u00e4rn. Enligt WHO\u00a0(http:\/\/www.who.int\/nutrition\/topics\/ida\/en\/) \u00e4r &#8220;j\u00e4rnbrist den vanligaste och mest utbredda n\u00e4ringsst\u00f6rningen i v\u00e4rlden&#8221;. Inofer \u00e4r registrerad i Frankrike.<\/p>\n<p>&#8220;Det h\u00e4r \u00e4r steg tv\u00e5 i v\u00e5r sj\u00e4lvf\u00f6rs\u00f6rjningsresa i \u00e5r &#8211; kommenterar VD f\u00f6r Double Bond Pharmaceutical AB Igor Lokot. &#8211; Inofer \u00e4r ett bepr\u00f6vat preparat med unika egenskaper och f\u00f6rv\u00e4ntas att generera Double Bond Pharmas int\u00e4kter redan under Q3 &#8211; Q4 2018&#8221;.<\/p>\n<p><a href=\"http:\/\/translate.google.com\/translate?hl=en&amp;sl=auto&amp;tl=en&amp;u=http%3A%2F%2Fwww.doctissimo.fr%2Fmedicament-INOFER.htm\" target=\"_blank\" rel=\"noopener noreferrer\">Mer om Inofer<\/a><\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-text fusion-text-3\"><h4>Nyhetsk\u00e4lla<\/h4>\n<\/div><div class=\"fusion-text fusion-text-4\"><p><a href=\"https:\/\/www.spotlightstockmarket.com\/sv\/market-overview\/nyheter\/nyhets-artikel\/?id=42830&amp;publisher=370\" target=\"_blank\" rel=\"noopener noreferrer\">Spotlight<\/a><\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-sharing-box fusion-sharing-box-1 boxed-icons has-taglines layout-floated layout-medium-floated layout-small-floated\" style=\"background-color:#f6f6f6;--awb-layout:row;--awb-alignment-small:space-between;\" data-title=\"Double Bond Pharmaceutical blir distribut\u00f6r av Inofer\" data-description=\"Double Bond Pharmaceutical blir distribut\u00f6r av Inofer    Double Bond Pharmaceutical och Laboratoire XO har idag, den 2018-02-06, signerat ett distributionsavtal f\u00f6r Inofer i Sverige, Norge, Danmark och Finland. Inofer \u00e4r ett j\u00e4rntillskott som best\u00e5r av ferrous succinat som \u00e4r en kemisk j\u00e4rnform k\u00e4nd f\u00f6r att l\u00e4ttare upptas i\" data-link=\"https:\/\/www.drugsson.com\/sv\/double-bond-pharmaceutical-blir-distributor-av-inofer\/\"><h4 class=\"tagline\" style=\"color:#4c5166;\">Dela inl\u00e4gget<\/h4><div class=\"fusion-social-networks sharingbox-shortcode-icon-wrapper sharingbox-shortcode-icon-wrapper-1 boxed-icons\"><span><a href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharmaceutical-blir-distributor-av-inofer%2F&amp;t=Double%20Bond%20Pharmaceutical%20blir%20distribut%C3%B6r%20av%20Inofer\" target=\"_blank\" rel=\"noreferrer\" title=\"Facebook\" aria-label=\"Facebook\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"Facebook\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-facebook awb-icon-facebook\" style=\"color:#ffffff;background-color:#3b5998;border-color:#3b5998;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/x.com\/intent\/post?text=Double%20Bond%20Pharmaceutical%20blir%20distribut%C3%B6r%20av%20Inofer&amp;url=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharmaceutical-blir-distributor-av-inofer%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"X\" aria-label=\"X\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"X\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-twitter awb-icon-twitter\" style=\"color:#ffffff;background-color:#000000;border-color:#000000;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/www.linkedin.com\/shareArticle?mini=true&amp;url=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharmaceutical-blir-distributor-av-inofer%2F&amp;title=Double%20Bond%20Pharmaceutical%20blir%20distribut%C3%B6r%20av%20Inofer&amp;summary=Double%20Bond%20Pharmaceutical%20blir%20distribut%C3%B6r%20av%20Inofer%20%20%20%20%20%20%20%0D%0A%0D%0ADouble%20Bond%20Pharmaceutical%20och%20Laboratoire%20XO%20har%20idag%2C%20den%202018-02-06%2C%20signerat%20ett%20distributionsavtal%20f%C3%B6r%20Inofer%20i%20Sverige%2C%20Norge%2C%20Danmark%20och%20Finland.%20Inofer%20%C3%A4r%20ett%20j%C3%A4rntillskott%20som%20best%C3%A5r%20av%20ferrous%20succinat%20som%20%C3%A4r%20en%20kemisk%20j%C3%A4rnform%20k%C3%A4nd%20f%C3%B6r%20att%20l%C3%A4ttare%20upptas%20i\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"LinkedIn\" aria-label=\"LinkedIn\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"LinkedIn\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-linkedin awb-icon-linkedin\" style=\"color:#ffffff;background-color:#0077b5;border-color:#0077b5;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19,4],"tags":[],"_links":{"self":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/954"}],"collection":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/comments?post=954"}],"version-history":[{"count":5,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/954\/revisions"}],"predecessor-version":[{"id":1362,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/954\/revisions\/1362"}],"wp:attachment":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/media?parent=954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/categories?post=954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/tags?post=954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}